Identification

Name
Gemfibrozil
Accession Number
DB01241  (APRD00293)
Type
Small Molecule
Groups
Approved
Description

A lipid-regulating agent that lowers elevated serum lipids primarily by decreasing serum triglycerides with a variable reduction in total cholesterol. These decreases occur primarily in the VLDL fraction and less frequently in the LDL fraction. Gemfibrozil increases HDL subfractions HDL2 and HDL3 as well as apolipoproteins A-I and A-II. Its mechanism of action has not been definitely established. [PubChem]

Structure
Thumb
Synonyms
  • 2,2-Dimethyl-5-(2,5-dimethylphenoxy)valeriansaeure
  • 2,2-Dimethyl-5-(2,5-xylyloxy)valeriansaeure
  • 2,2-Dimethyl-5-(2,5-xylyloxy)valeric acid
  • Gemfibrozil
  • Gemfibrozilo
  • Gemfibrozilum
External IDs
CI-719
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Dom-gemfibrozilTablet600 mgOralDominion Pharmacal1998-10-222013-04-05Canada
Dom-gemfibrozilCapsule300 mgOralDominion Pharmacal2000-03-10Not applicableCanada
Gemfibrozil Cap 300mgCapsule300 mgOralOmni Laboratories Division, Warner Lambert Canada Inc.1990-12-312003-07-04Canada
Gemfibrozil Tab 600mgTablet600 mgOralOmni Laboratories Division, Warner Lambert Canada Inc.1991-12-312003-07-04Canada
Gemfibrozil-300 - CapCapsule300 mgOralPro Doc Limitee1995-12-312010-07-13Canada
Gemfibrozil-600 - Tab 600mgTablet600 mgOralPro Doc Limitee1995-12-312015-07-10Canada
LopidTablet, film coated600 mg/1OralRemedy Repack2017-08-16Not applicableUs
LopidTablet, film coated600 mg/1OralParke Davis Div Of Pfizer Inc2004-03-30Not applicableUs
Lopid 600mgTablet600 mgOralPfizer1987-12-312013-07-18Canada
Lopid Cap 300mgCapsule300 mgOralPfizer1984-12-312013-07-18Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-gemfibrozilTablet600 mgOralApotex Corporation1993-12-31Not applicableCanada
Apo-gemfibrozil Cap 300mg USPCapsule300 mgOralApotex Corporation1993-12-31Not applicableCanada
GemfibrozilTablet600 mg/1OralKaiser Foundations Hospitals2016-11-29Not applicableUs
GemfibrozilTablet600 mg/1OralClinical Solutions Wholsesale2011-01-012017-08-12Us
GemfibrozilTablet, film coated600 mg/1OralMc Kesson Contract Packaging2011-09-19Not applicableUs
GemfibrozilTablet600 mg/1OralRemedy Repack2011-07-192016-10-28Us
GemfibrozilTablet600 mg/1OralClinical Solutions Wholsesale2011-01-012017-06-29Us
GemfibrozilTablet, film coated600 mg/1OralMajor2010-03-12Not applicableUs
GemfibrozilTablet, film coated600 mg/1OralCardinal Health2010-03-12Not applicableUs
GemfibrozilTablet, film coated600 mg/1OralAmerincan Health Packaging2011-05-012017-12-31Us
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
GemfibrozilTablet600 mg/1OralDirectrx2017-10-27Not applicableUs
International/Other Brands
Gemlipid (Farmellas Enterprises) / Gen-Fibro / Genlip (Teofarma) / Jezil / Lipur (Pfizer) / Lopid
Categories
UNII
Q8X02027X3
CAS number
25812-30-0
Weight
Average: 250.3334
Monoisotopic: 250.15689457
Chemical Formula
C15H22O3
InChI Key
HEMJJKBWTPKOJG-UHFFFAOYSA-N
InChI
InChI=1S/C15H22O3/c1-11-6-7-12(2)13(10-11)18-9-5-8-15(3,4)14(16)17/h6-7,10H,5,8-9H2,1-4H3,(H,16,17)
IUPAC Name
5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoic acid
SMILES
CC1=CC(OCCCC(C)(C)C(O)=O)=C(C)C=C1

Pharmacology

Indication

For treatment of adult patients with very high elevations of serum triglyceride levels (types IV and V hyperlipidemia) who are at risk of developing pancreatitis (inflammation of the pancreas) and who do not respond adequately to a strict diet.

Structured Indications
Pharmacodynamics

Gemfibrozil, a fibric acid antilipemic agent similar to clofibrate, is used to treat hyperlipoproteinemia and as a second-line therapy for type IIb hypercholesterolemia. It acts to reduce triglyceride levels, reduce VLDL levels, reduce LDL levels (moderately), and increase HDL levels (moderately).

Mechanism of action

Gemfibrozil increases the activity of extrahepatic lipoprotein lipase (LL), thereby increasing lipoprotein triglyceride lipolysis. It does so by activating Peroxisome proliferator-activated receptor-alpha (PPARα) 'transcription factor ligand', a receptor that is involved in metabolism of carbohydrates and fats, as well as adipose tissue differentiation. This increase in the synthesis of lipoprotein lipase thereby increases the clearance of triglycerides. Chylomicrons are degraded, VLDLs are converted to LDLs, and LDLs are converted to HDL. This is accompanied by a slight increase in secretion of lipids into the bile and ultimately the intestine. Gemfibrozil also inhibits the synthesis and increases the clearance of apolipoprotein B, a carrier molecule for VLDL.

TargetActionsOrganism
APeroxisome proliferator-activated receptor alpha
agonist
Human
Absorption

Well absorbed from gastrointestinal tract (within 1-2 hours).

Volume of distribution
Not Available
Protein binding

95%

Metabolism

Hepatic. Gemfibrozil mainly undergoes oxidation of a ring methyl group to successively form a hydroxymethyl and a carboxyl metabolite.

Route of elimination

Approximately seventy percent of the administered human dose is excreted in the urine, mostly as the glucuronide conjugate, with less than 2% excreted as unchanged gemfibrozil.

Half life

1.5 hours

Clearance
Not Available
Toxicity

Oral, mouse: LD50 = 3162 mg/kg. Symptoms of overdose include abdominal cramps, diarrhea, joint and muscle pain, nausea, and vomiting.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AceclofenacThe metabolism of Aceclofenac can be decreased when combined with Gemfibrozil.Approved, Investigational
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Gemfibrozil.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Gemfibrozil.Approved
AcetohexamideGemfibrozil may increase the hypoglycemic activities of Acetohexamide.Investigational, Withdrawn
Acetylsalicylic acidThe metabolism of Acetylsalicylic acid can be decreased when combined with Gemfibrozil.Approved, Vet Approved
AcipimoxAcipimox may increase the myopathic rhabdomyolysis activities of Gemfibrozil.Approved, Investigational
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Gemfibrozil.Approved
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Gemfibrozil.Approved, Investigational
AlosetronThe metabolism of Alosetron can be decreased when combined with Gemfibrozil.Approved, Withdrawn
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Gemfibrozil.Approved, Illicit, Investigational
AmbrisentanThe metabolism of Ambrisentan can be decreased when combined with Gemfibrozil.Approved, Investigational
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Gemfibrozil.Approved, Withdrawn
AmiodaroneThe metabolism of Gemfibrozil can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Gemfibrozil.Approved
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Gemfibrozil.Approved, Investigational
AmoxicillinThe metabolism of Amoxicillin can be decreased when combined with Gemfibrozil.Approved, Vet Approved
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Gemfibrozil.Approved
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Gemfibrozil.Approved
ApixabanThe metabolism of Apixaban can be decreased when combined with Gemfibrozil.Approved
AprepitantThe serum concentration of Gemfibrozil can be increased when it is combined with Aprepitant.Approved, Investigational
Arachidonic AcidThe metabolism of Arachidonic Acid can be decreased when combined with Gemfibrozil.Experimental
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Gemfibrozil.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Gemfibrozil.Approved, Investigational
ArtemetherThe metabolism of Artemether can be decreased when combined with Gemfibrozil.Approved
AtazanavirThe metabolism of Gemfibrozil can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Atomoxetine can be decreased when combined with Gemfibrozil.Approved
AtorvastatinGemfibrozil may increase the myopathic rhabdomyolysis activities of Atorvastatin.Approved
AxitinibThe metabolism of Axitinib can be decreased when combined with Gemfibrozil.Approved, Investigational
AzelastineThe metabolism of Azelastine can be decreased when combined with Gemfibrozil.Approved
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Gemfibrozil.Approved
BexaroteneThe serum concentration of Bexarotene can be increased when it is combined with Gemfibrozil.Approved, Investigational
BoceprevirThe metabolism of Gemfibrozil can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Bortezomib can be decreased when combined with Gemfibrozil.Approved, Investigational
BosentanThe serum concentration of Bosentan can be increased when it is combined with Gemfibrozil.Approved, Investigational
BrivaracetamThe metabolism of Brivaracetam can be decreased when combined with Gemfibrozil.Approved, Investigational
BromazepamThe metabolism of Bromazepam can be decreased when combined with Gemfibrozil.Approved, Illicit
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Gemfibrozil.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Gemfibrozil.Approved
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Gemfibrozil.Approved, Investigational
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Gemfibrozil.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Bupropion can be decreased when combined with Gemfibrozil.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Gemfibrozil.Approved
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Gemfibrozil.Approved
CaffeineThe metabolism of Caffeine can be decreased when combined with Gemfibrozil.Approved
CandesartanThe metabolism of Candesartan can be decreased when combined with Gemfibrozil.Experimental
Candesartan cilexetilThe metabolism of Candesartan cilexetil can be decreased when combined with Gemfibrozil.Approved
CarbamazepineThe metabolism of Gemfibrozil can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Gemfibrozil.Approved
CarbutamideGemfibrozil may increase the hypoglycemic activities of Carbutamide.Experimental
CarisoprodolThe metabolism of Carisoprodol can be decreased when combined with Gemfibrozil.Approved
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Gemfibrozil.Approved, Investigational
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Gemfibrozil.Approved, Investigational
CeritinibThe serum concentration of Gemfibrozil can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Gemfibrozil.Withdrawn
Chenodeoxycholic acidThe therapeutic efficacy of Chenodeoxycholic acid can be decreased when used in combination with Gemfibrozil.Approved
ChloramphenicolThe metabolism of Chloramphenicol can be decreased when combined with Gemfibrozil.Approved, Vet Approved
ChlorpropamideThe metabolism of Chlorpropamide can be decreased when combined with Gemfibrozil.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Gemfibrozil resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Gemfibrozil.Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Gemfibrozil.Approved, Investigational
CiprofibrateThe risk or severity of adverse effects can be increased when Ciprofibrate is combined with Gemfibrozil.Approved, Investigational
CisaprideThe metabolism of Cisapride can be decreased when combined with Gemfibrozil.Approved, Investigational, Withdrawn
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Gemfibrozil.Approved
ClarithromycinThe metabolism of Gemfibrozil can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Gemfibrozil can be decreased when combined with Clemastine.Approved
ClobazamThe metabolism of Clobazam can be decreased when combined with Gemfibrozil.Approved, Illicit
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Gemfibrozil.Investigational
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Gemfibrozil.Approved, Vet Approved
ClopidogrelThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Gemfibrozil resulting in a loss in efficacy.Approved, Nutraceutical
ClorindioneGemfibrozil may increase the anticoagulant activities of Clorindione.Experimental
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Gemfibrozil.Approved, Illicit
ClotrimazoleThe metabolism of Gemfibrozil can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Clozapine can be decreased when combined with Gemfibrozil.Approved
CobicistatThe metabolism of Gemfibrozil can be decreased when combined with Cobicistat.Approved
ColchicineGemfibrozil may increase the myopathic rhabdomyolysis activities of Colchicine.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Gemfibrozil resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Gemfibrozil resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ConivaptanThe serum concentration of Gemfibrozil can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Gemfibrozil can be decreased when combined with Crizotinib.Approved
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Gemfibrozil.Approved, Investigational
CyclosporineCyclosporine may increase the nephrotoxic activities of Gemfibrozil.Approved, Investigational, Vet Approved
DabrafenibThe serum concentration of Gemfibrozil can be decreased when it is combined with Dabrafenib.Approved
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Gemfibrozil.Approved
DapsoneThe metabolism of Dapsone can be decreased when combined with Gemfibrozil.Approved, Investigational
DarunavirThe metabolism of Gemfibrozil can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Gemfibrozil can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Gemfibrozil can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Gemfibrozil can be decreased when combined with Delavirdine.Approved
DesipramineThe metabolism of Desipramine can be decreased when combined with Gemfibrozil.Approved
DexlansoprazoleThe metabolism of Dexlansoprazole can be decreased when combined with Gemfibrozil.Approved
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Gemfibrozil.Approved
DiazepamThe metabolism of Diazepam can be decreased when combined with Gemfibrozil.Approved, Illicit, Vet Approved
DiclofenacThe serum concentration of Diclofenac can be increased when it is combined with Gemfibrozil.Approved, Vet Approved
DicoumarolGemfibrozil may increase the anticoagulant activities of Dicoumarol.Approved
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Gemfibrozil.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Gemfibrozil.Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Gemfibrozil.Experimental
DihydroergotamineThe metabolism of Gemfibrozil can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Gemfibrozil.Approved
DiphenadioneGemfibrozil may increase the anticoagulant activities of Diphenadione.Experimental
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Gemfibrozil.Approved
DoconexentThe metabolism of Doconexent can be decreased when combined with Gemfibrozil.Approved, Investigational
DolasetronThe metabolism of Dolasetron can be decreased when combined with Gemfibrozil.Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Gemfibrozil.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Gemfibrozil.Approved
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Gemfibrozil.Approved
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Gemfibrozil.Approved
DoxepinThe metabolism of Doxepin can be decreased when combined with Gemfibrozil.Approved
DoxycyclineThe metabolism of Gemfibrozil can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Gemfibrozil.Approved, Illicit
DronedaroneThe metabolism of Gemfibrozil can be decreased when combined with Dronedarone.Approved
EletriptanThe metabolism of Eletriptan can be decreased when combined with Gemfibrozil.Approved, Investigational
EluxadolineThe serum concentration of Eluxadoline can be increased when it is combined with Gemfibrozil.Approved
EnasidenibThe metabolism of Enasidenib can be decreased when combined with Gemfibrozil.Approved
EnfuvirtideThe metabolism of Enfuvirtide can be decreased when combined with Gemfibrozil.Approved, Investigational
EnzalutamideThe serum concentration of Gemfibrozil can be decreased when it is combined with Enzalutamide.Approved
EpoprostenolThe metabolism of Epoprostenol can be decreased when combined with Gemfibrozil.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Gemfibrozil.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Gemfibrozil.Approved
ErythromycinThe metabolism of Gemfibrozil can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe metabolism of Escitalopram can be decreased when combined with Gemfibrozil.Approved, Investigational
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Gemfibrozil.Approved, Investigational
EstradiolThe metabolism of Estradiol can be decreased when combined with Gemfibrozil.Approved, Investigational, Vet Approved
EstroneThe metabolism of Estrone can be decreased when combined with Gemfibrozil.Approved
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Gemfibrozil.Approved
Ethyl biscoumacetateGemfibrozil may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtizolamThe metabolism of Etizolam can be decreased when combined with Gemfibrozil.Approved
EtodolacThe metabolism of Etodolac can be decreased when combined with Gemfibrozil.Approved, Investigational, Vet Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Gemfibrozil.Approved, Investigational
EtravirineThe metabolism of Etravirine can be decreased when combined with Gemfibrozil.Approved
EzetimibeThe risk or severity of adverse effects can be increased when Gemfibrozil is combined with Ezetimibe.Approved
FamotidineThe metabolism of Famotidine can be decreased when combined with Gemfibrozil.Approved
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Gemfibrozil.Approved
FluconazoleThe metabolism of Gemfibrozil can be decreased when combined with Fluconazole.Approved
FluindioneGemfibrozil may increase the anticoagulant activities of Fluindione.Investigational
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Gemfibrozil.Approved
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Gemfibrozil.Approved, Illicit
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Gemfibrozil.Approved, Vet Approved
FlurbiprofenThe metabolism of Flurbiprofen can be decreased when combined with Gemfibrozil.Approved, Investigational
FlutamideThe metabolism of Flutamide can be decreased when combined with Gemfibrozil.Approved
FluvastatinGemfibrozil may increase the myopathic rhabdomyolysis activities of Fluvastatin.Approved
FluvoxamineThe metabolism of Gemfibrozil can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolThe metabolism of Formoterol can be decreased when combined with Gemfibrozil.Approved, Investigational
FosamprenavirThe metabolism of Gemfibrozil can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Gemfibrozil can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Gemfibrozil can be increased when combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Gemfibrozil can be increased when it is combined with Fusidic Acid.Approved
GavestinelThe metabolism of Gavestinel can be decreased when combined with Gemfibrozil.Investigational
GlibornurideGemfibrozil may increase the hypoglycemic activities of Glibornuride.Investigational, Withdrawn
GliclazideThe metabolism of Gliclazide can be decreased when combined with Gemfibrozil.Approved
GlimepirideThe metabolism of Glimepiride can be decreased when combined with Gemfibrozil.Approved
GlipizideThe metabolism of Glipizide can be decreased when combined with Gemfibrozil.Approved
GliquidoneGemfibrozil may increase the hypoglycemic activities of Gliquidone.Approved, Investigational
GlisoxepideGemfibrozil may increase the hypoglycemic activities of Glisoxepide.Approved, Investigational
GlucosamineThe metabolism of Glucosamine can be decreased when combined with Gemfibrozil.Approved
GlyburideThe metabolism of Glyburide can be decreased when combined with Gemfibrozil.Approved
GuanfacineThe metabolism of Guanfacine can be decreased when combined with Gemfibrozil.Approved, Investigational
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Gemfibrozil.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Gemfibrozil.Approved, Vet Approved
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Gemfibrozil.Approved
HistamineThe metabolism of Histamine can be decreased when combined with Gemfibrozil.Approved, Investigational
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Gemfibrozil.Approved, Illicit
IbuprofenThe metabolism of Ibuprofen can be decreased when combined with Gemfibrozil.Approved
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Gemfibrozil.Approved
IdelalisibThe serum concentration of Gemfibrozil can be increased when it is combined with Idelalisib.Approved
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Gemfibrozil.Approved
ImatinibThe serum concentration of the active metabolites of Imatinib can be reduced when Imatinib is used in combination with Gemfibrozil resulting in a loss in efficacy.Approved
ImipramineThe metabolism of Imipramine can be decreased when combined with Gemfibrozil.Approved
IndinavirThe metabolism of Gemfibrozil can be decreased when combined with Indinavir.Approved
indisulamThe metabolism of indisulam can be decreased when combined with Gemfibrozil.Investigational
IndomethacinThe metabolism of Indomethacin can be decreased when combined with Gemfibrozil.Approved, Investigational
IrbesartanThe metabolism of Irbesartan can be decreased when combined with Gemfibrozil.Approved, Investigational
IrinotecanThe serum concentration of the active metabolites of Irinotecan can be increased when Irinotecan is used in combination with Gemfibrozil.Approved, Investigational
IsavuconazoniumThe metabolism of Gemfibrozil can be decreased when combined with Isavuconazonium.Approved, Investigational
IsradipineThe metabolism of Gemfibrozil can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Gemfibrozil can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Gemfibrozil can be increased when it is combined with Ivacaftor.Approved
IxazomibThe metabolism of Ixazomib can be decreased when combined with Gemfibrozil.Approved
KetamineThe metabolism of Ketamine can be decreased when combined with Gemfibrozil.Approved, Vet Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Gemfibrozil.Approved, Investigational
KetoconazoleThe metabolism of Gemfibrozil can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe metabolism of Ketoprofen can be decreased when combined with Gemfibrozil.Approved, Vet Approved
LacosamideThe serum concentration of Lacosamide can be increased when it is combined with Gemfibrozil.Approved
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Gemfibrozil.Approved, Investigational
LapatinibThe metabolism of Lapatinib can be decreased when combined with Gemfibrozil.Approved, Investigational
LeflunomideThe metabolism of Leflunomide can be decreased when combined with Gemfibrozil.Approved, Investigational
LesinuradThe metabolism of Lesinurad can be decreased when combined with Gemfibrozil.Approved
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Gemfibrozil.Approved
LicofeloneThe metabolism of Licofelone can be decreased when combined with Gemfibrozil.Investigational
LidocaineThe metabolism of Lidocaine can be decreased when combined with Gemfibrozil.Approved, Vet Approved
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Gemfibrozil.Approved, Investigational
LopinavirThe metabolism of Gemfibrozil can be decreased when combined with Lopinavir.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Gemfibrozil.Approved
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Gemfibrozil.Approved
LornoxicamThe metabolism of Lornoxicam can be decreased when combined with Gemfibrozil.Approved, Investigational
LosartanThe metabolism of Losartan can be decreased when combined with Gemfibrozil.Approved
LovastatinGemfibrozil may increase the myopathic rhabdomyolysis activities of Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Gemfibrozil can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Gemfibrozil can be increased when combined with Lumacaftor.Approved
LumiracoxibThe metabolism of Lumiracoxib can be decreased when combined with Gemfibrozil.Approved, Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Gemfibrozil.Illicit, Investigational, Withdrawn
MacitentanThe metabolism of Macitentan can be decreased when combined with Gemfibrozil.Approved
Mefenamic acidThe metabolism of Mefenamic acid can be decreased when combined with Gemfibrozil.Approved
MelatoninThe metabolism of Melatonin can be decreased when combined with Gemfibrozil.Approved, Nutraceutical, Vet Approved
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Gemfibrozil.Approved, Vet Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Gemfibrozil.Investigational, Withdrawn
MeprobamateThe metabolism of Meprobamate can be decreased when combined with Gemfibrozil.Approved, Illicit
MestranolThe metabolism of Mestranol can be decreased when combined with Gemfibrozil.Approved
MetahexamideGemfibrozil may increase the hypoglycemic activities of Metahexamide.Experimental
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Gemfibrozil.Experimental
MethadoneThe metabolism of Methadone can be decreased when combined with Gemfibrozil.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Gemfibrozil.Approved, Investigational, Vet Approved
MethsuximideThe metabolism of Methsuximide can be decreased when combined with Gemfibrozil.Approved
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Gemfibrozil.Approved
MethylphenobarbitalThe metabolism of Methylphenobarbital can be decreased when combined with Gemfibrozil.Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Gemfibrozil.Approved
MetoprololThe metabolism of Metoprolol can be decreased when combined with Gemfibrozil.Approved, Investigational
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Gemfibrozil.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Gemfibrozil.Experimental
MifepristoneThe serum concentration of Gemfibrozil can be increased when it is combined with Mifepristone.Approved, Investigational
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Gemfibrozil.Approved
MitotaneThe serum concentration of Gemfibrozil can be decreased when it is combined with Mitotane.Approved
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Gemfibrozil.Approved
MontelukastThe serum concentration of Montelukast can be increased when it is combined with Gemfibrozil.Approved
NaproxenThe metabolism of Naproxen can be decreased when combined with Gemfibrozil.Approved, Vet Approved
NateglinideThe metabolism of Nateglinide can be decreased when combined with Gemfibrozil.Approved, Investigational
NefazodoneThe metabolism of Gemfibrozil can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Gemfibrozil can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Gemfibrozil can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Gemfibrozil can be increased when combined with Nevirapine.Approved
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Gemfibrozil.Approved, Investigational
NiclosamideThe metabolism of Niclosamide can be decreased when combined with Gemfibrozil.Approved, Investigational, Vet Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Gemfibrozil.Approved
NilotinibThe metabolism of Gemfibrozil can be decreased when combined with Nilotinib.Approved, Investigational
NilutamideThe metabolism of Nilutamide can be decreased when combined with Gemfibrozil.Approved
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Gemfibrozil.Approved
OlaparibThe metabolism of Gemfibrozil can be decreased when combined with Olaparib.Approved
OlodaterolThe metabolism of Olodaterol can be decreased when combined with Gemfibrozil.Approved
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Gemfibrozil.Approved, Investigational, Vet Approved
OndansetronThe metabolism of Ondansetron can be decreased when combined with Gemfibrozil.Approved
OsimertinibThe serum concentration of Gemfibrozil can be increased when it is combined with Osimertinib.Approved
OspemifeneThe serum concentration of Ospemifene can be increased when it is combined with Gemfibrozil.Approved
OxaprozinThe metabolism of Oxaprozin can be decreased when combined with Gemfibrozil.Approved
OxiconazoleThe metabolism of Oxiconazole can be decreased when combined with Gemfibrozil.Approved
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Gemfibrozil.Approved, Vet Approved
PalbociclibThe serum concentration of Gemfibrozil can be increased when it is combined with Palbociclib.Approved
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Gemfibrozil.Approved
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Gemfibrozil.Approved
ParecoxibThe serum concentration of Parecoxib can be increased when it is combined with Gemfibrozil.Approved
PentamidineThe metabolism of Pentamidine can be decreased when combined with Gemfibrozil.Approved
PentobarbitalThe metabolism of Gemfibrozil can be increased when combined with Pentobarbital.Approved, Vet Approved
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Gemfibrozil.Approved, Investigational, Vet Approved, Withdrawn
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Gemfibrozil.Approved
PethidineThe metabolism of Pethidine can be decreased when combined with Gemfibrozil.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Gemfibrozil.Withdrawn
PhenindioneGemfibrozil may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenobarbitalThe metabolism of Gemfibrozil can be increased when combined with Phenobarbital.Approved
PhenprocoumonGemfibrozil may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe metabolism of Phenylbutazone can be decreased when combined with Gemfibrozil.Approved, Vet Approved
PhenytoinThe metabolism of Gemfibrozil can be increased when combined with Phenytoin.Approved, Vet Approved
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Gemfibrozil.Approved, Investigational
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Gemfibrozil.Approved, Investigational
PiroxicamThe metabolism of Piroxicam can be decreased when combined with Gemfibrozil.Approved, Investigational
PitavastatinGemfibrozil may increase the myopathic rhabdomyolysis activities of Pitavastatin.Approved
PodofiloxThe metabolism of Podofilox can be decreased when combined with Gemfibrozil.Approved
PosaconazoleThe metabolism of Gemfibrozil can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Gemfibrozil.Approved
PravastatinGemfibrozil may increase the myopathic rhabdomyolysis activities of Pravastatin.Approved
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Gemfibrozil.Approved, Vet Approved
PrimidoneThe metabolism of Gemfibrozil can be increased when combined with Primidone.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Gemfibrozil.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Gemfibrozil.Approved
PromazineThe metabolism of Promazine can be decreased when combined with Gemfibrozil.Approved, Vet Approved
PropofolThe metabolism of Propofol can be decreased when combined with Gemfibrozil.Approved, Investigational, Vet Approved
PropranololThe metabolism of Propranolol can be decreased when combined with Gemfibrozil.Approved, Investigational
QuazepamThe metabolism of Quazepam can be decreased when combined with Gemfibrozil.Approved, Illicit
QuetiapineThe metabolism of Quetiapine can be decreased when combined with Gemfibrozil.Approved
QuinidineThe metabolism of Quinidine can be decreased when combined with Gemfibrozil.Approved
QuinineThe metabolism of Quinine can be decreased when combined with Gemfibrozil.Approved
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Gemfibrozil.Approved, Investigational
RaltegravirRaltegravir may increase the myopathic rhabdomyolysis activities of Gemfibrozil.Approved
RamelteonThe serum concentration of Ramelteon can be increased when it is combined with Gemfibrozil.Approved, Investigational
RanitidineThe metabolism of Ranitidine can be decreased when combined with Gemfibrozil.Approved
RanolazineThe metabolism of Gemfibrozil can be decreased when combined with Ranolazine.Approved, Investigational
RepaglinideThe serum concentration of Repaglinide can be increased when it is combined with Gemfibrozil.Approved, Investigational
RifabutinThe metabolism of Gemfibrozil can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Gemfibrozil can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Gemfibrozil can be increased when combined with Rifapentine.Approved
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Gemfibrozil.Investigational, Withdrawn
RomidepsinThe metabolism of Romidepsin can be decreased when combined with Gemfibrozil.Approved, Investigational
RosiglitazoneThe metabolism of Rosiglitazone can be decreased when combined with Gemfibrozil.Approved, Investigational
RosuvastatinGemfibrozil may increase the myopathic rhabdomyolysis activities of Rosuvastatin.Approved
RupatadineThe metabolism of Rupatadine can be decreased when combined with Gemfibrozil.Approved
Salicylic acidThe metabolism of Salicylic acid can be decreased when combined with Gemfibrozil.Approved, Vet Approved
SaquinavirThe metabolism of Gemfibrozil can be decreased when combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Gemfibrozil.Approved
SelegilineThe metabolism of Selegiline can be decreased when combined with Gemfibrozil.Approved, Investigational, Vet Approved
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Gemfibrozil.Approved
SertralineThe metabolism of Sertraline can be decreased when combined with Gemfibrozil.Approved
SildenafilThe metabolism of Sildenafil can be decreased when combined with Gemfibrozil.Approved, Investigational
SiltuximabThe serum concentration of Gemfibrozil can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Gemfibrozil can be increased when it is combined with Simeprevir.Approved
SimvastatinGemfibrozil may increase the myopathic rhabdomyolysis activities of Simvastatin.Approved
SitaxentanThe metabolism of Sitaxentan can be decreased when combined with Gemfibrozil.Approved, Investigational, Withdrawn
St. John's WortThe serum concentration of Gemfibrozil can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Gemfibrozil can be increased when it is combined with Stiripentol.Approved
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Gemfibrozil.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Gemfibrozil.Approved
SulfamoxoleThe metabolism of Sulfamoxole can be decreased when combined with Gemfibrozil.Approved
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Gemfibrozil.Approved
SulfisoxazoleThe metabolism of Sulfisoxazole can be decreased when combined with Gemfibrozil.Approved, Vet Approved
SuprofenThe metabolism of Suprofen can be decreased when combined with Gemfibrozil.Approved, Withdrawn
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Gemfibrozil.Approved
TapentadolThe metabolism of Tapentadol can be decreased when combined with Gemfibrozil.Approved
TelaprevirThe metabolism of Gemfibrozil can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Gemfibrozil can be decreased when combined with Telithromycin.Approved
TemazepamThe metabolism of Temazepam can be decreased when combined with Gemfibrozil.Approved
TeniposideThe metabolism of Teniposide can be decreased when combined with Gemfibrozil.Approved
TenoxicamThe metabolism of Tenoxicam can be decreased when combined with Gemfibrozil.Approved
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Gemfibrozil.Approved, Investigational, Vet Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Gemfibrozil.Withdrawn
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Gemfibrozil.Experimental
TestosteroneThe metabolism of Testosterone can be decreased when combined with Gemfibrozil.Approved, Investigational
ThalidomideThe metabolism of Thalidomide can be decreased when combined with Gemfibrozil.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Theophylline can be decreased when combined with Gemfibrozil.Approved
ThiamylalThe metabolism of Thiamylal can be decreased when combined with Gemfibrozil.Approved, Vet Approved
ThioridazineThe metabolism of Thioridazine can be decreased when combined with Gemfibrozil.Approved, Withdrawn
TiclopidineThe metabolism of Ticlopidine can be decreased when combined with Gemfibrozil.Approved
TimololThe metabolism of Timolol can be decreased when combined with Gemfibrozil.Approved
TioclomarolGemfibrozil may increase the anticoagulant activities of Tioclomarol.Experimental
TipranavirThe metabolism of Tipranavir can be decreased when combined with Gemfibrozil.Approved, Investigational
TocilizumabThe serum concentration of Gemfibrozil can be decreased when it is combined with Tocilizumab.Approved
TofacitinibThe metabolism of Tofacitinib can be decreased when combined with Gemfibrozil.Approved, Investigational
TolazamideGemfibrozil may increase the hypoglycemic activities of Tolazamide.Approved
TolbutamideThe metabolism of Tolbutamide can be decreased when combined with Gemfibrozil.Approved
TolterodineThe metabolism of Tolterodine can be decreased when combined with Gemfibrozil.Approved, Investigational
TorasemideThe metabolism of Torasemide can be decreased when combined with Gemfibrozil.Approved
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Gemfibrozil.Approved, Investigational
TreprostinilThe metabolism of Treprostinil can be decreased when combined with Gemfibrozil.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Gemfibrozil.Approved, Investigational, Nutraceutical
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Gemfibrozil.Approved
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Gemfibrozil.Approved, Vet Approved
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Gemfibrozil.Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Gemfibrozil.Investigational, Withdrawn
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Gemfibrozil.Approved, Experimental
Ursodeoxycholic acidThe therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Gemfibrozil.Approved, Investigational
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Gemfibrozil.Investigational, Withdrawn
Valproic AcidThe metabolism of Valproic Acid can be decreased when combined with Gemfibrozil.Approved, Investigational
ValsartanThe metabolism of Valsartan can be decreased when combined with Gemfibrozil.Approved, Investigational
VenlafaxineThe metabolism of Venlafaxine can be decreased when combined with Gemfibrozil.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Gemfibrozil.Approved
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Gemfibrozil.Investigational
VismodegibThe metabolism of Vismodegib can be decreased when combined with Gemfibrozil.Approved
VoriconazoleThe metabolism of Gemfibrozil can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Gemfibrozil.Approved
WarfarinThe metabolism of Warfarin can be decreased when combined with Gemfibrozil.Approved
XimelagatranThe metabolism of Ximelagatran can be decreased when combined with Gemfibrozil.Approved, Investigational, Withdrawn
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Gemfibrozil.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Gemfibrozil.Approved, Investigational
ZaltoprofenThe metabolism of Zaltoprofen can be decreased when combined with Gemfibrozil.Approved, Investigational
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Gemfibrozil.Approved
ZileutonThe metabolism of Zileuton can be decreased when combined with Gemfibrozil.Approved, Investigational, Withdrawn
ZiprasidoneThe metabolism of Gemfibrozil can be decreased when combined with Ziprasidone.Approved
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Gemfibrozil.Approved
ZopicloneThe metabolism of Zopiclone can be decreased when combined with Gemfibrozil.Approved
Food Interactions
  • Take 30 minutes before meals.

References

Synthesis Reference

Gianfranco Piccoli, Antonio Tarquini, Giovanni Frare, "Process for the preparation of gemfibrozil." U.S. Patent US5654476, issued May, 1980.

US5654476
General References
Not Available
External Links
Human Metabolome Database
HMDB15371
KEGG Drug
D00334
KEGG Compound
C07020
PubChem Compound
3463
PubChem Substance
46508264
ChemSpider
3345
BindingDB
50110590
ChEBI
5296
ChEMBL
CHEMBL457
Therapeutic Targets Database
DAP000210
PharmGKB
PA449750
IUPHAR
3439
Guide to Pharmacology
GtP Drug Page
HET
4TX
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Gemfibrozil
ATC Codes
C10AB04 — Gemfibrozil
AHFS Codes
  • 24:06.06 — Fribic Acid Derivatives
PDB Entries
5boj
FDA label
Download (260 KB)
MSDS
Download (74.3 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Active Not RecruitingPreventionPreclinical Alzheimer's Disease1
1CompletedNot AvailableDrug-Drug Interaction (DDI) / Healthy Volunteers / Pharmacokinetics1
1CompletedNot AvailableHealthy Volunteers1
1CompletedBasic ScienceDrug-Drug Interaction (DDI) / Healthy Volunteers1
1CompletedBasic ScienceHealthy Volunteers2
1CompletedOtherAnemias1
1CompletedTreatmentBioavailability1
1CompletedTreatmentCancers1
1CompletedTreatmentHealthy Volunteers3
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
1CompletedTreatmentHypertriglyceridemias1
1CompletedTreatmentType 2 Diabetes Mellitus2
2CompletedTreatmentCardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Heart Diseases / Myocardial Ischemia1
2CompletedTreatmentNicotine Dependence1
2RecruitingTreatmentCessation, Smoking1
3CompletedTreatmentCoronary Heart Disease (CHD)1
4WithdrawnTreatmentAtherosclerosis1
Not AvailableCompletedNot AvailableHealthy Volunteers1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
TabletOral600 mg/1
Tablet, coatedOral600 mg/1
Tablet, film coatedOral600 mg/1
CapsuleOral300 mg
TabletOral600 mg
Prices
Unit descriptionCostUnit
Gemfibrozil powder2.88USD g
Lopid 600 mg tablet2.07USD tablet
Gemfibrozil 600 mg tablet1.8USD tablet
Apo-Gemfibrozil 600 mg Tablet0.65USD tablet
Mylan-Gemfibrozil 600 mg Tablet0.65USD tablet
Novo-Gemfibrozil 600 mg Tablet0.65USD tablet
Nu-Gemfibrozil 600 mg Tablet0.65USD tablet
Pms-Gemfibrozil 600 mg Tablet0.65USD tablet
Lopid 300 mg Capsule0.58USD capsule
Apo-Gemfibrozil 300 mg Capsule0.31USD capsule
Mylan-Gemfibrozil 300 mg Capsule0.31USD capsule
Novo-Gemfibrozil 300 mg Capsule0.31USD capsule
Nu-Gemfibrozil 300 mg Capsule0.31USD capsule
Pms-Gemfibrozil 300 mg Capsule0.31USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)62 °CPhysProp
boiling point (°C)158.5 °C at 2.00E-02 mm HgPhysProp
water solubility10 mg/mL (in base)Not Available
logP3.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0278 mg/mLALOGPS
logP3.61ALOGPS
logP4.39ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)4.42ChemAxon
pKa (Strongest Basic)-4.8ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area46.53 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity71.82 m3·mol-1ChemAxon
Polarizability28.9 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.977
Blood Brain Barrier+0.9213
Caco-2 permeable+0.7918
P-glycoprotein substrateSubstrate0.5597
P-glycoprotein inhibitor INon-inhibitor0.8943
P-glycoprotein inhibitor IINon-inhibitor0.8839
Renal organic cation transporterNon-inhibitor0.8177
CYP450 2C9 substrateNon-substrate0.7512
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.6973
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 inhibitorInhibitor0.8949
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8234
Ames testNon AMES toxic0.7822
CarcinogenicityNon-carcinogens0.8314
BiodegradationNot ready biodegradable0.6759
Rat acute toxicity2.2167 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9774
hERG inhibition (predictor II)Non-inhibitor0.8701
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-00di-0900000000-24b892a8bd68bdf9cef6
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-00di-0900000000-7a9eaaae65f0e1efcbc4
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-00di-0900000000-12b36ea4be2a1b876c61
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-00di-0900000000-647692900acca2ec2441
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-00di-0900000000-41c8e4e08162dfaf1fc4
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-00di-0900000000-28d25da91cc1d391cc84
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-00di-0900000000-a08267bdc97edb1a2601
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-00di-0900000000-a133a90a69b988c45ffb
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0059-6910000000-0ad597adcb83e9f4e4ba
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0059-8900000000-8684ba342d3eb0a7f602
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-05cr-9400000000-008385b887cc6ac6d748
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0ac0-9300000000-74e1b5c007dd49af6a01
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0ab9-9200000000-cc36aaee7c70d8e92f96
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-9100000000-ce28ed926945c33079d6
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenol ethers. These are aromatic compounds containing an ether group substituted with a benzene ring.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Phenol ethers
Sub Class
Not Available
Direct Parent
Phenol ethers
Alternative Parents
p-Xylenes / Phenoxy compounds / Alkyl aryl ethers / Monocarboxylic acids and derivatives / Carboxylic acids / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Phenoxy compound / P-xylene / Xylene / Phenol ether / Alkyl aryl ether / Monocyclic benzene moiety / Carboxylic acid derivative / Carboxylic acid / Ether / Monocarboxylic acid or derivatives
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
aromatic ether (CHEBI:5296)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Ligand-activated transcription factor. Key regulator of lipid metabolism. Activated by the endogenous ligand 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (16:0/18:1-GPC). Activated by oleyleth...
Gene Name
PPARA
Uniprot ID
Q07869
Uniprot Name
Peroxisome proliferator-activated receptor alpha
Molecular Weight
52224.595 Da
References
  1. Clavey V, Copin C, Mariotte MC, Bauge E, Chinetti G, Fruchart J, Fruchart JC, Dallongeville J, Staels B: Cell culture conditions determine apolipoprotein CIII secretion and regulation by fibrates in human hepatoma HepG2 cells. Cell Physiol Biochem. 1999;9(3):139-49. [PubMed:10494028]
  2. Bosse Y, Pascot A, Dumont M, Brochu M, Prud'homme D, Bergeron J, Despres JP, Vohl MC: Influences of the PPAR alpha-L162V polymorphism on plasma HDL(2)-cholesterol response of abdominally obese men treated with gemfibrozil. Genet Med. 2002 Jul-Aug;4(4):311-5. [PubMed:12172398]
  3. Pahan K, Jana M, Liu X, Taylor BS, Wood C, Fischer SM: Gemfibrozil, a lipid-lowering drug, inhibits the induction of nitric-oxide synthase in human astrocytes. J Biol Chem. 2002 Nov 29;277(48):45984-91. Epub 2002 Sep 18. [PubMed:12244038]
  4. Shoji Y, Sanekata A, Sato M, Imaizumi K: Preparation of antiserum against rat delta6-desaturase and its use to evaluate the desaturase protein levels in rats treated with gemfibrozil, a ligand for peroxisome proliferator-activated receptor alpha. Biosci Biotechnol Biochem. 2003 May;67(5):1177-8. [PubMed:12834305]
  5. Rizvi F, Iftikhar M, George JP: Beneficial effects of fish liver preparations of sea bass (Lates calcarifer) versus gemfibrozil in high fat diet-induced lipid-intolerant rats. J Med Food. 2003 Summer;6(2):123-8. [PubMed:12935323]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Details
2. Cytochrome P450 2C9
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Honkalammi J, Niemi M, Neuvonen PJ, Backman JT: Gemfibrozil is a strong inactivator of CYP2C8 in very small multiple doses. Clin Pharmacol Ther. 2012 May;91(5):846-55. doi: 10.1038/clpt.2011.313. [PubMed:22472994]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostagland...
Gene Name
SLCO1B1
Uniprot ID
Q9Y6L6
Uniprot Name
Solute carrier organic anion transporter family member 1B1
Molecular Weight
76447.99 Da
References
  1. Sharma P, Holmes VE, Elsby R, Lambert C, Surry D: Validation of cell-based OATP1B1 assays to assess drug transport and the potential for drug-drug interaction to support regulatory submissions. Xenobiotica. 2010 Jan;40(1):24-37. doi: 10.3109/00498250903351013. [PubMed:19919292]

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 20:34